Cross-over Trials in Clinical Research

Stephen Senn has worked for the NHS in England, as a lecturer in Scotland and in drug development in Switzerland (with CIBA-Geigy). Until recently he was Professor of Pharmaceutical and Health Statistics at University College London but since September 2003 he has been  Professor of Statistics at Glasgow University. His books, Cross-over Trials in Clinical Research (1993, 2nd edition 2002) and Statistical Issues in Drug Development (1997) are published by Wiley and his latest book, Dicing with Death (2003) by Cambridge University Press. In 2001, he was the first recipient of the George C Challis award for biostatistics of the University of Florida. He is a member of the editorial boards of Statistics in Medicine, Statistical Methods in Medical Research, Pharmaceutical Statistics and Applied Clinical Trials and is a section editor for the Wiley Statistics in Practice series.

• Preface to the Second Edition. Preface to the First Edition. 1. Introduction. 2. Some Basic Considerations Concerning Estimation in Clinical Trials. 3. The AB/BA Design with Normal Data. 4. Other Outcomes and the AB/BA Design. 5. Normal Data from Designs with Three or More Treatments. 6. Other Outcomes from Designs with Three or More Treatments. 7. Some Special Designs. 8. Graphical and Tabular Presentation of Cross-over Trials. 9. Various Design Issues. 10. Mathematical Approaches to Carry-over. References. Author Index. Subject Index.

"…clearly written…mode of presentation is very effective…I recommend this book as a useful resource…" (Journal of the American Statistical Association, December 2004) "The book by Senn was the very first volume in Wiley's excellent series, "Statistics in Practice".  Here, 10 years later, it is now the first of the books in that series to reappear in a second addition.” (Technometrics, May 2004)"...well structured and easy to read...incredibly useful..." (Applied Clinical Trials, December 2002)"...an excellent reference source and is easily readable." (The Statistician)"...explanation are kept as non-technical as possible, although they do not lack statistical rigour...well worth reading..." (Pharmaceutical Statistics, Vol 2, 2003)“…the main additions can be seen as …adding to the arguments for the author’s view on carryover affects...” (Clinical Trials, No.1 2004)